PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: quiz answers

IFU: JusChek SARS-CoV-2 Antigen Rapid Test (Nasal Swab ...

SARS-CoV-2 Antigen Rapid Test (Nasal Swab) Package Insert For Self-testing REF INCP-502H English Before testing, scan the QR code to watch the how to use video. A Rapid test for the qualitative detection of SARS-CoV-2 Nucleocapsid Protein antigens present in nasal swab specimen. For self-testing in vitro diagnostic use. INTENDED USE The SARS-CoV-2 Antigen Rapid Test (Nasal Swab) is a lateral flow chromatographic immunoassay single-use test kit intended to qualitative detect the SARS-CoV-2 that causes COVID-19 with self-collected nasal swab specimen. The test is intended for use in symptomatic individuals meeting the case definition for COVID-19 within the first 7 days of symptom onset.

Streptococcus sp group F, Chlamydia pneumoniae Legionella pneumophila Philadelphia Bordetella Pertussis A639,Mycoplasma Pneumoniae M129. CROSS-REACTIVITY CONTINUED Our Test Results indicated there is the cross reactivity between SARS-CoV …

Fullscreen Download

Tags:

  Tests, Chlamydia

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of IFU: JusChek SARS-CoV-2 Antigen Rapid Test (Nasal Swab ...

Documents from same domain

COVID-19 rapid antigen self-tests

www.tga.gov.au

COVID-19 rapid antigen self-tests. This guidance refe rs to COVID -19 (caused by SARS-CoV-2) only and does not include self-tests to detect other types of coronavirus , or COVID_19 rapid antibody tests . COVID-19 rapid antigen self-tests are tests that allow individuals to collect a specimen, conduct a test and interpret the results by themselves.

  Rapid

Guideline for the labelling of medicines

www.tga.gov.au

Guideline for the labelling medicines of istorical consultation document Draft - Version 1.0, August 2014

  Guidelines, Labelling, Guideline for the labelling

Australian public assessment report for Linagliptin

www.tga.gov.au

• An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.

  Assessment, Report, Public, Australian, Public assessment, Australian public assessment report for linagliptin, Linagliptin

Australian Public Assessment Report for Silodosin

www.tga.gov.au

Australian Public Assessment Report for Silodosin Proprietary Product Name: Urorec ... • To report a problem with a medicine or medical device, please see the information on ... //www.tga.gov.au>. About AusPARs • An Australian Public Assessment Re port (AusPAR) provides information about the evaluation of a prescription medicine and the ...

  Assessment, Report, Public, Australian, Ports, Australian public assessment report for silodosin, Silodosin, Public assessment re port

Guidance 18: Impurities in drug substances and …

www.tga.gov.au

Therapeutic Goods Administration Guidance 18: Impurities in drug substances and drug products V1.0 August 2013 Page 3 of 13 Version history Version Description of change Author Effective date

  Drug, Impurities, Substance, Impurities in drug substances and, Impurities in drug substances and drug

Explanatory notes for pharmaceutical manufacturers on the ...

www.tga.gov.au

PE 008-4 3 of 8 1 January 2011 4. SCOPE These Explanatory Notes apply to the preparation and content of the Site Master File. Manufacturers should refer to regional / …

  Notes, Pharmaceutical, Life, Manufacturers, Explanatory notes, Explanatory, Explanatory notes for pharmaceutical manufacturers

The use of GMDN codes for IVD medical devices in Australia

www.tga.gov.au

Global Medical Device Nomenclature (GMDN) The GMDN is an international nomenclature system used by regional or national regulatory bodies to consistently describe medical devices: 1 • consistent assessment of devices before they are approved for supply . GMDN codes are used to

  Devices, Medical, Global, Nomenclature, Global medical device nomenclature

COMIRNATY™ COVID-19 VACCINE

www.tga.gov.au

Do not receive this vaccine if you are allergic to any of these ingredients. What COMIRNATY looks like COMIRNATY is a white to off-white suspension provided in a multidose clear glass vial. After dilution, each vial contains 6 doses of vaccine. AUST R 346290. Who distributes COMIRNATY Pfizer Australia Pty Ltd Sydney NSW www.pfizer.com.au

  Ingredients, Vaccine

AUSTRALIAN PRODUCT INFORMATION (ChAdOx1-S) …

www.tga.gov.au

AUSTRALIAN PRODUCT INFORMATION COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection . 1 NAME OF THE MEDICINE . ChAdOx1-S (provisional ABN) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION . Each multi-dose vial contains 5x10. 11. viral particles (vp) of (ChAdOx1-S . a, b) in 5 mL. One dose (0.5 mL) contains 5x10. 10. vp of …

  Information, Product, Name, Product information, Qualitative, Astrazeneca

Australian public assessment report for BNT162b2 (mRNA)

www.tga.gov.au

The RNA is encapsulated in lipid nanoparticles (LNPs), which enables entry into host cells, expression of the S protein, and elicitation of both antibody and cellular immune responses. The vaccine is supplied as a white to off white sterile frozen liquid, packaged in a multi dose clear glass 2 mL vial with a rubber stopper,

  Lipids, Nanoparticles, Lipid nanoparticles

Related documents

British Columbia Treatment Guidelines

www.bccdc.ca

Chlamydia - Chlamydia trachomatis If Lymphogranuloma Venereum (LGV) is suspected please contact the Provinicial STI/HIV Clinic Physician and refer to LGV Section. Considerations - Pregnancy/Lactation • A test of cure (TOC) should be performed 3 - 4 weeks after initiation of treatment for all pregnant or lactating women.

  Tests, Chlamydia

MLN006818 - Clinical Laboratory Fee Schedule - CMS

www.cms.gov

Chlamydia, gonorrhea, syphilis, hepatitis B, and hepatitis C ... In general, the CLFS test payment paid on or after . January 1, 2018, equals the weighted median of private payor rates for the test, based on the applicable information collected and reported. The data collection, reporting, and payment updates generally happen

  Tests, Laboratory, Schedule, Clinical, Chlamydia, Clinical laboratory fee schedule

Rapid SARS-COV-2 Antigen Test Card Self-test - tga.gov.au

www.tga.gov.au

Rapid SARS-CoV-2 Antigen Test Card is a one step lateral flow test for the detection of SARS-CoV-2 virus antigen in nasal swabs from individuals suspected of having COVID-19. The Rapid SARS-CoV-2 Antigen Test Card cannot be used as the sole basis to diagnose or exclude SARS-CoV-2 infection. Children under 14 years of age should be assisted by an

  Tests

Related search queries

Chlamydia, Test, Clinical Laboratory Fee Schedule